**TDMS No.** 93020 - 03 **Test Type:** 90-DAY

Route: SKIN APPLICATION

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

DIISOPROPYLCARBODIIMIDE

**CAS Number:** 693-13-0

Species/Strain: RATS/F 344 Pathologist: BIERLEY, B. - STEDHAM, M. - SHANAHAN, P.

Final #2/Rats

**C Number:** C93020

**Lock Date:** 05/16/1995

Cage Range: ALL

Date Range: ALL

**Reasons For Removal:** ALL

Removal Date Range: ALL

Treatment Groups: Include ALL

**Date Report Reqsted:** 08/08/2005 **Time Report Reqsted:** 08:53:32 **First Dose M/F:** 09/06/94 / 09/07/94

Test Type: 90-DAY

Route: SKIN APPLICATION
Species/Strain: RATS/F 344

### P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

DIISOPROPYLCARBODIIMIDE

**CAS Number:** 693-13-0

Pathologist: BIERLEY, B. - STEDHAM, M. - SHANAHAN, P.

**Date Report Reqsted:** 08/08/2005 **Time Report Reqsted:** 08:53:32 **First Dose M/F:** 09/06/94 / 09/07/94

FISCHER 344 RATS MALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG	80 MG/KG	160 MG/KG
Disposition Summary						
Animals Initially in Study	10	10	10	10	10	10
Early Deaths Moribund Sacrifice Natural Death					10	3 7
Survivors Terminal Sacrifice	10	10	10	10		
Animals Examined Microscopically	10	10	10	10	10	10
ALIMENTARY SYSTEM						
Liver Centrilobular, Congestion Centrilobular, Vacuolization Cytoplasmic	(10)	(0)	(0)	(10)	(10) 4 (40%) 1 (10%)	(10) 6 (60%) 6 (60%)
Periportal, Vacuolization Cytoplasmic Pancreas	1 (10%) (10)	(0)	(0)	(10)	(10)	(9)
Acinus, Atrophy, Focal Stomach, Glandular Infiltration Cellular, Mixed Cell Cyst	1 (10%) (10)	(0)	(0)	(10) 1 (10%) 1 (10%)	(10)	(10)
CARDIOVASCULAR SYSTEM						
Heart Cardiomyopathy Artery, Inflammation, Chronic Active	(10) 4 (40%)	(10) 4 (40%)	(10) 6 (60%)	(10) 4 (40%)	(10) 5 (50%) 1 (10%)	(10) 3 (30%)
ENDOCRINE SYSTEM						
None						
GENERAL BODY SYSTEM						
None						

a - Number of animals examined microscopically at site and number of animals with lesion

# **TDMS No.** 93020 - 03 **Test Type:** 90-DAY

Route: SKIN APPLICATION

Species/Strain: RATS/F 344

### P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

### DIISOPROPYLCARBODIIMIDE

**CAS Number:** 693-13-0

Pathologist: BIERLEY, B. - STEDHAM, M. - SHANAHAN, P.

**Date Report Reqsted:** 08/08/2005 **Time Report Reqsted:** 08:53:32 **First Dose M/F:** 09/06/94 / 09/07/94

Lab: MBA

FISCHER 344 RATS MALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG	80 MG/KG	160 MG/KG
GENITAL SYSTEM						
Preputial Gland Inflammation, Chronic Active	(10) 2 (20%)	(0)	(0)	(10) 2 (20%)	(10) 1 (10%)	(10) 4 (40%)
HEMATOPOIETIC SYSTEM						
Bone Marrow	(10)	(0)	(0)	(10)	(10)	(10)
Hemorrhage Lymph Node, Mandibular Hyperplasia, Lymphoid Hyperplasia, Plasma Cell	(10) 1 (10%) 1 (10%)	(0)	(0)	(10)	(10)	2 (20%) (10)
Hemorrhage Lymph Node, Mesenteric Necrosis	(10) 1 (10%)	(0)	(0)	1 (10%) (10)	(10)	(10)
Spleen	(10)	(10)	(10)	(10)	(10)	(10)
Lymphoid Follicle, Depletion Cellular Thymus Necrosis Hemorrhage	(10)	(10)	(10)	(10)	(10) 2 (20%) 2 (20%)	1 (10%) (10)
Atrophy					2 (20%)	3 (30%)
INTEGUMENTARY SYSTEM						
Skin Epidermis, Skin, Site Of Application,	(10)	(10) 5 (50%)	(10) 7 (70%)	(10) 10 (100%)	(10) 10 (100%)	(10) 3 (30%)
Hyperplasia Epidermis, Skin, Site Of Application,						9 (90%)
Necrosis, Focal Skin, Site Of Application, Inflammation, Chronic Active				1 (10%)	7 (70%)	10 (100%

None

**NERVOUS SYSTEM** 

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: 90-DAY

Route: SKIN APPLICATION
Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

DIISOPROPYLCARBODIIMIDE

**CAS Number:** 693-13-0

Pathologist: BIERLEY, B. - STEDHAM, M. - SHANAHAN, P.

**Date Report Reqsted:** 08/08/2005 **Time Report Reqsted:** 08:53:32 **First Dose M/F:** 09/06/94 / 09/07/94

FISCHER 344 RATS MALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG	80 MG/KG	160 MG/KG
Brain Edema, Focal Hemorrhage Congestion Arteriole, Necrosis, Fibrinoid	(10)	(10)	(10)	(10)	(10) 5 (50%) 1 (10%)	(10) 1 (10%) 4 (40%) 1 (10%) 1 (10%)
Neuron, Necrosis					8 (80%)	1 (1070)
RESPIRATORY SYSTEM						
Lung Congestion Hemorrhage Alveolus, Infiltration Cellular, Histiocyte Interstitium, Inflammation, Chronic Active	(10) 1 (10%) 1 (10%)	(0)	(0)	(10)	(10) 5 (50%) 1 (10%) 1 (10%) 1 (10%)	(10) 8 (80%)
Perivascular, Infiltration Cellular,	3 (30%)			6 (60%)	1 (10%)	
Lymphocyte Nose Respiratory Epithelium, Inflammation,	(10) 3 (30%)	(0)	(0)	(10) 1 (10%)	(10) 1 (10%)	(10) 5 (50%)
Chronic Active Respiratory Epithelium, Metaplasia, Squamous						3 (30%)
Squamous Epithelium, Inflammation, Chronic				1 (10%)		
Squamous Epithelium, Inflammation, Chronic Active						1 (10%)
SPECIAL SENSES SYSTEM						
Eye Cornea, Bilateral, Degeneration, Focal	(0)	(0)	(0)	(0)	(1) 1 (100%)	(0)
URINARY SYSTEM						
Kidney Nephropathy	(10) 5 (50%)	(0)	(0)	(10) 2 (20%)	(10)	(10)

a - Number of animals examined microscopically at site and number of animals with lesion

**TDMS No.** 93020 - 03 **Test Type:** 90-DAY

Route: SKIN APPLICATION
Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

DIISOPROPYLCARBODIIMIDE

**CAS Number:** 693-13-0

Pathologist: BIERLEY, B. - STEDHAM, M. - SHANAHAN, P.

**Date Report Reqsted:** 08/08/2005 **Time Report Reqsted:** 08:53:32 **First Dose M/F:** 09/06/94 / 09/07/94

Lab: MBA

FISCHER 344 RATS MALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG 80 MG/KG 160 MG/KG

\*\*\* END OF MALE \*\*\*

Test Type: 90-DAY

Route: SKIN APPLICATION Species/Strain: RATS/F 344

### P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

### DIISOPROPYLCARBODIIMIDE

**CAS Number:** 693-13-0

Pathologist: BIERLEY, B. - STEDHAM, M. - SHANAHAN, P.

**Date Report Reqsted:** 08/08/2005 **Time Report Reqsted:** 08:53:32 **First Dose M/F:** 09/06/94 / 09/07/94

FISCHER 344 RATS FEMALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG	80 MG/KG	160 MG/KG
Disposition Summary						
Animals Initially in Study	10	10	10	10	10	10
Early Deaths Moribund Sacrifice					10	10
Survivors Accidently Killed Terminal Sacrifice Animals Examined Microscopically	1 9 10	10 10	10 10	10 10	10	10
ALIMENTARY SYSTEM						
Liver Congestion	(10)	(0)	(0)	(10)	(10) 1 (10%)	(10)
Centrilobular, Congestion Mesentery	(0)	(0)	(0)	(1)	(0)	2 (20%) (0)
Fat, Necrosis Pancreas Acinus, Cytoplasmic Alteration, Focal	(10) 1 (10%)	(0)	(0)	1 (100%) (10)	(10)	(10)
CARDIOVASCULAR SYSTEM						
Heart Cardiomyopathy	(10)	(10)	(10) 1 (10%)	(10) 2 (20%)	(10) 2 (20%)	(10)
ENDOCRINE SYSTEM						
Adrenal Cortex Hypertrophy, Focal	(10) 1 (10%)	(0)	(0)	(10)	(10)	(10)
GENERAL BODY SYSTEM						
None						
GENITAL SYSTEM						
Clitoral Gland	(8)	(0)	(0)	(6)	(10)	(10)

a - Number of animals examined microscopically at site and number of animals with lesion

### P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

DIISOPROPYLCARBODIIMIDE

**CAS Number:** 693-13-0

Pathologist: BIERLEY, B. - STEDHAM, M. - SHANAHAN, P.

**Date Report Reqsted:** 08/08/2005 **Time Report Reqsted:** 08:53:32 **First Dose M/F:** 09/06/94 / 09/07/94

Lab: MBA

FISCHER 344 RATS FEMALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG	80 MG/KG	160 MG/KG
Inflammation, Chronic Active Ovary	(10)	(0)	(0)	1 (17%) (10)	2 (20%) (10)	1 (10%) (10)
Cyst	(10)	(0)	(0)	1 (10%)	(10)	(10)
Uterus Hydrometra	(10)	(1)	(5) 5 (100%)	(10) 4 (40%)	(10)	(10) 1 (10%)
HEMATOPOIETIC SYSTEM						
Bone Marrow Hyperplasia, Focal, Lymphoid Hyperplasia, Focal, Histiocytic	(10)	(0)	(0)	(10) 1 (10%) 2 (20%)	(10)	(10)
Hemorrhage				(,	1 (10%)	2 (20%)
Atrophy Lymph Node, Mandibular	(10)	(0)	(0)	(9)	1 (10%) (9)	(10)
Hemorrhage	(10)	(0)	(0)	(9)	1 (11%)	(10)
Hyperplasia, Lymphoid					1 (11%)	2 (20%)
Lymph Node, Mesenteric	(10)	(0)	(0)	(10)	(10)	(10)
Hyperplasia, Histiocytic Hyperplasia, Lymphoid	1 (10%)			1 (10%) 1 (10%)		
Thymus Atrophy	(10)	(10)	(10)	(10)	(10) 4 (40%)	(10) 1 (10%)
INTEGUMENTARY SYSTEM						
Skin	(10)	(10)	(10)	(10)	(10)	(10)
Epidermis, Skin, Site Of Application,	1 (10%)	2 (20%)	3 (30%)	5 (50%)	10 (100%)	10 (100%
Hyperplasia Epidermis, Skin, Site Of Application,						10 (100%
Necrosis, Focal						10 (100%
Skin, Site Of Application, Inflammation, Chronic Active					7 (70%)	10 (100%
MUSCULOSKELETAL SYSTEM						_
None						
NERVOUS SYSTEM						
Brain	(10)	(10)	(10)	(10)	(10)	(10)
	· - /	\ -/	( - )	· - /	· - /	( -)

a - Number of animals examined microscopically at site and number of animals with lesion

**TDMS No.** 93020 - 03

Route: SKIN APPLICATION

Species/Strain: RATS/F 344

Test Type: 90-DAY

Route: SKIN APPLICATION

Test Type: 90-DAY

Species/Strain: RATS/F 344

### P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

DIISOPROPYLCARBODIIMIDE

**CAS Number:** 693-13-0

Pathologist: BIERLEY, B. - STEDHAM, M. - SHANAHAN, P.

Date Report Reqsted: 08/08/2005 Time Report Reqsted: 08:53:32 First Dose M/F: 09/06/94 / 09/07/94

Lab: MBA

FISCHER 344 RATS FEMALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG	80 MG/KG	160 MG/K0
Edema, Focal Hemorrhage Arteriole, Necrosis, Fibrinoid Neuron, Necrosis					5 (50%) 5 (50%) 1 (10%) 8 (80%)	2 (20% 6 (60% 2 (20%
RESPIRATORY SYSTEM						
Lung Congestion Hemorrhage	(10)	(0)	(0)	(10)	(10) 5 (50%) 1 (10%)	(10) 8 (80%
Interstitium, Inflammation, Chronic Active Perivascular, Infiltration Cellular, Lymphocyte	1 (10%) 4 (40%)			3 (30%) 5 (50%)	4 (40%)	
Nose Olfactory Epithelium, Atrophy Olfactory Epithelium, Inflammation, Chronic Active	(10) 1 (10%)	(0)	(0)	(10) 1 (10%)	(10)	(10)
Respiratory Epithelium, Atrophy Respiratory Epithelium, Inflammation, Chronic Active	1 (10%)				1 (10%)	2 (20%
Squamous Epithelium, Inflammation, Chronic Active					1 (10%)	
SPECIAL SENSES SYSTEM						
None						
URINARY SYSTEM						
Kidney Congestion	(10)	(0)	(0)	(10)	(10) 1 (10%)	(10) 1 (10%
Medulla, Mineralization Urinary Bladder Serosa, Mineralization	5 (50%) (10)	(0)	(0)	6 (60%) (10) 1 (10%)	10 (100%) (10)	3 (30% (10)

\*\*\* END OF REPORT \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion